Caribou Biosciences to Participate in Upcoming Investor Conferences
15 févr. 2024 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Global CRISPR Genomic Cure Market Set to Soar with 29.21% CAGR till 2028, Driven by Tech Advancements and Therapeutic Expansion
08 févr. 2024 10h00 HE
|
Research and Markets
Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The "Crispr Genomic Cure Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ...
Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors
30 janv. 2024 08h00 HE
|
Tome Biosciences
Tome Biosciences appoints Daniel Curran, MD, to its Board of Directors.
Global CRISPR Gene Detection and Diagnostic Market Assessment 2023-2027: Focus on Applications, Organisms, and Key Players in the Industry
16 janv. 2024 04h28 HE
|
Research and Markets
Dublin, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Gene Detection and Diagnostic Markets by Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides, 2023...
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
07 janv. 2024 11h00 HE
|
Caribou Biosciences, Inc.
-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...
Tome Biosciences Acquires Replace Therapeutics
02 janv. 2024 09h00 HE
|
Tome Biosciences
Tome acquires Replace Therapeutics.
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
12 déc. 2023 16h02 HE
|
Caribou Biosciences, Inc.
-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial...
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform
12 déc. 2023 07h57 HE
|
Tome Biosciences
Tome Biosciences launches with over $200 million in funding to advance programmable genomic integration (PGI).
Global Enzymatic DNA Synthesis Market Analysis, Trends and Forecasts to 2028 - Opportunities in CRISPR-Cas9 Integration and Cell-Free Synthetic Biology
12 déc. 2023 05h23 HE
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "Global Enzymatic DNA Synthesis Market: Analysis By Product Type (DNA Library Synthesis and Custom DNA Synthesis), By Technology (PCR, CRISPR, SOLA and...
Epic Bio to Present at the Upcoming CRISPR2.0 Conference
21 nov. 2023 12h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...